Thromboembolism events in patients receiving previous antithrombotics
| TE events . | Pilot* . | TRIUMPH . | SHEPHERD . | Extension† (all studies) . |
|---|---|---|---|---|
| Before treatment | ||||
| Patients, no. | 9 | 23 | 51 | 103 |
| TE events, no.‡ | 4 | 9 | 26 | 40 |
| Patient-years, no. | 45.3 | 70.6 | 168.2 | 377.1 |
| TE event rate, no. per 100 patient-years | 8.83 | 12.74 | 15.46 | 10.61 |
| Eculizumab treatment | ||||
| Patients, no. | 9 | 23 | 51 | 103 |
| TE events, no. | 0 | 0 | 0 | 1 |
| Patient-years, no. | 28.8 | 11.9 | 51.0 | 161.9 |
| TE event rate, no. per 100 patient-years | 0.00 | 0.00 | 0.00 | 0.62§ |
| TE events . | Pilot* . | TRIUMPH . | SHEPHERD . | Extension† (all studies) . |
|---|---|---|---|---|
| Before treatment | ||||
| Patients, no. | 9 | 23 | 51 | 103 |
| TE events, no.‡ | 4 | 9 | 26 | 40 |
| Patient-years, no. | 45.3 | 70.6 | 168.2 | 377.1 |
| TE event rate, no. per 100 patient-years | 8.83 | 12.74 | 15.46 | 10.61 |
| Eculizumab treatment | ||||
| Patients, no. | 9 | 23 | 51 | 103 |
| TE events, no. | 0 | 0 | 0 | 1 |
| Patient-years, no. | 28.8 | 11.9 | 51.0 | 161.9 |
| TE event rate, no. per 100 patient-years | 0.00 | 0.00 | 0.00 | 0.62§ |
Includes a 1-year and a 2-year extension study.
Includes TRIUMPH placebo-treated patients who transitioned to eculizumab treatment in the phase 3 extension study.
To qualify as a TE event on antithrombotic therapy, the event must have been verified to have occurred more than 2 weeks following initiation of antithrombotics.
P < .001 for comparisons of eculizumab treatment versus before treatment, signed rank test.